新規抗癌剤の評価ネダプラチン二剤併用療法

摘要

目的．非小細胞肺癌患者を対象としてNedaplatinとVinorelbineあるいはGemcitabineとの併用療法の有用性について検討した．方法．VQ療法－Nedaplatin80mg/m~2（day1）＋Vinorelbine25mg/m~2（day1，8）を3週間隔投与とした．GQ療法－Nedaplatin80mg/m~2（day8）＋GemcitabinelOOOmg/m~2（day1，8）を3週間間隔投与とした．結果．VQ療法は奏効率35.5％で，重篤な副作用はみられず有用性が高かったが，とくに扁平上皮癌において高かった．GQ療法は奏効率42.8％と高く，やはり重篤な副作用は認められなかった．これらはCisplatinとの併用療法と比較して大差はなかった．結論．NedaplatinはCisplatinと同等の効果を持つが，その副作用は少なく有用だと考えられたが，今後発展させるためにはさらなる試験が必要であろう．Objective. We evaluated the efficacy and toxicities of nedaplatin plus vinorelbine treatment and nedaplatin plus gemcitabine treatment in non small cell lung cancer patients. Methods. VQ-nedaplatin 80mg/m~2 (day 1) + vinorelbine 25mg/m~2 (day 1, 8) on every 3 weeks. GQ-nedaplatin 80mg/m~2 (day 8) + gemcitabine 1000mg/m~2(day 1, 8) on every 3 weeks. Results. The response rate was 35.5% or higher, especially in squamous cell carcinoma in VQ treatment. There were no serious side effects in VQ treatment. The response rate was 42.8% and there were no serious side effects in GQ treatment. These result were no different compared with Cisplatin-based treatment. Conclusion.Nedaplatin may be useful as cisplatin and has no serious side effects, but it further evaluation will be necessary .